Impact of posttransplant G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.

Posted by rob on October 25, 2005 under Uncategorized | Be the First to Comment

Khoury HJ, Loberiza FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, Martino R, McCarthy PL, Tiberghien P, Verdonck LF, Horowitz MM

Blood. 2005 Oct 20;

Granulocyte-colony-stimulating factor (G-CSF) is often administered after hematopoietic cell transplantation (HCT) to accelerate neutrophil recovery, but it is unclear what impact G-CSF has on long-term transplant outcomes. We analyzed within the database of the Center for International Blood and Marrow Transplant Research, the impact of giving posttransplant G-CSF on the outcomes of allogeneic HCT for acute myelogenous leukemia and chronic myelogenous leukemia in 2,719 patients transplanted between 1995 and 2000. These included 1,435 recipients of HLA-identical sibling bone marrow (BM), 609 recipients of HLA-identical peripheral blood stem cells (PBSC), and 675 recipients of unrelated donor BM transplants. Outcomes were compared between patients receiving or not receiving G-CSF within 7 days of HCT according to graft type. Median follow-up was >30 mo (range, 2-87 mo). G-CSF shortened the post-transplant neutropenic period, but did not affect days +30 and +100 treatment-related mortality (TRM). Probabilities of acute and chronic graft-versus-host disease (GVHD), leukemia-free (LFS) and overall survival were similar whether or not G-CSF was given. Multivariate analyses confirmed that giving G-CSF did not affect the risk of GVHD, TRM, LFS, or survival. In conclusion, results of this study found no long-term benefit or disadvantage of giving G-CSF posttransplant to promote hematopoietic recovery.

Impact of posttransplant G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.